July 2010
Worldwide Biotech;Jul2010, Vol. 22 Issue 7, p4
Trade Publication
The article reports on the marketing authorization granted by the European Commission in July 2010 for Prolia, a drug developed by Amgen Inc. for the treatment of osteoporosis. Target consumers of the drug are postmenopausal women at increased risk of fractures and men with prostate cancer at increased risk of fractures. The components of the marketing authorization for Prolia are detailed. It offers information on the results from a related clinical trial.


Related Articles

  • FDA approves denosumab for treatment of postmenopausal osteoporosis.  // Endocrine Today;Jul2010, Vol. 8 Issue 7, p13 

    The article reports on the approval of denosumab, an injectable treatment for postmenopausal women with osteoporosis who are at risk for fractures from Amgen, by the U.S. Food and Drug Administration (FDA).

  • Amgen's Prolia Clears EU; U.S. Nod Expected Shortly. Boggs, Jennifer // BioWorld International;6/2/2010, Vol. 15 Issue 22, p3 

    The article announces the approval by European Union (EU) member states and Norway, Iceland and Liechtenstein of the Prolia drug from Amgen Inc. in the treatment of osteoporosis. The drug has been approved for use in postmenopausal women at risk of fractures and for bone loss in men with...

  • Amgen wins European marketing authorization grant for osteoporosis drug.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p15 

    The article reports that biotechnology company Amgen Inc. has received a marketing authorization grant from the European Commission for Prolia, which is used in treating osteoporosis in postmenopausal women at increased risk of fracture. The marketing authorization for Prolia comprises data from...

  • Amgen Files BLA for Denosumab in Bone Loss. Morrison, Trista // BioWorld Today;2/24/2009, Vol. 20 Issue 35, p6 

    The article reports that the biologics license application (BLA) of Amgen with the U.S. Food and Drug Administration (FDA) is seeking approval of denosumab for bone loss associated with osteoporosis in postmenopausal women, and that induced by hormone ablation therapy in prostate or breast...

  • WEEK IN WASHINGTON.  // BioWorld Insight;6/18/2012, Vol. 20 Issue 25, p6 

    The article offers news briefs from Washington on topics including the U.S. Supremen Court's hearing of the fraud of Amgen Inc., cancellation of an accelerated approval for Pfizer Inc.'s Celebrex, a drug, and actions of several U.S. House committes concerning penalties for counterfeiting of drugs.

  • Amgen Wins Approval for Repatha Cholesterol-Lowering Agent.  // Chain Drug Review;9/28/2015, Vol. 37 Issue 15, p106 

    The article reports on the approval of pharmaceutical firm Amgen Inc.'s Repatha cholesterol reducing drug.

  • Denosumab Receives Conditional Approval from FDA Expert Panel.  // Travel Medicine Advisor;Sep2009 Supplement, p2 

    The article reports on the conditional approval given by the U.S. Food and Drug Administration (FDA) Expert Panel on the new human monoclonal antibody denosumab. It cites that FDA has evaluated the drug for treatment of osteoporosis in men and women. It discusses the results of two...

  • Denosumab approved for treatment of postmenopausal osteoporosis. Tanzi, Maria G. // Pharmacy Today;Aug2010, Vol. 16 Issue 8, p34 

    The article reports on the approval of Denosumab (Prolia) for the treatment of postmenopausal osteoporosis by the U.S. Food and Drug Administration. It mentions that the drug, from Amgen Inc., is the first and only receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor available...

  • Epo, by any other name.  // Nature;9/20/2007, Vol. 449 Issue 7160, p259 

    The article reports that three companies for generic versions of the hormone erythropoietin had been granted marketing authorizations by the European Commission. The three companies include Amgen Inc., Johnson & Johnson and Sandoz AG. The approvals bring to five the number of follow-on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics